News | April 09, 2026
OPPI and NIPER Raebareli partner to boost pharma research and talent
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
At the center of deployment is mlHealth360’s proprietary Scaida AI platform, designed to detect and triage abnormalities in CT scans
Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Subscribe To Our Newsletter & Stay Updated
